Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

11.1%

1 terminated/withdrawn out of 9 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

11%

1 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 1

7(77.8%)

Phase 2

1(11.1%)

Phase 3

1(11.1%)

9Total

Phase 1(7)

Phase 2(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT05671510Phase 3Recruiting

ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

Role: lead

NCT05682443Phase 1Active Not Recruiting

ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC

Role: lead

NCT06352359Phase 1Recruiting

Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors

Role: lead

NCT07408258Phase 1Not Yet Recruiting

Safety, Pharmacokinetics (PK), and Efficacy of ONC-783 in Advanced Solid Tumors

Role: lead

NCT05446298Phase 2Active Not Recruiting

ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer

Role: lead

NCT06635785Phase 1Recruiting

Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors

Role: lead

NCT05858736Phase 1Active Not Recruiting

Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors

Role: lead

NCT04140526Phase 1Active Not Recruiting

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

Role: lead

NCT06219499Phase 1Withdrawn

Safety, Tolerability, Immunogenicity and Pharmacokinetics of ONC-841

Role: lead

All 9 trials loaded